CA2331332A1 - Anti-angiogenic proteins and methods of use thereof - Google Patents
Anti-angiogenic proteins and methods of use thereof Download PDFInfo
- Publication number
- CA2331332A1 CA2331332A1 CA002331332A CA2331332A CA2331332A1 CA 2331332 A1 CA2331332 A1 CA 2331332A1 CA 002331332 A CA002331332 A CA 002331332A CA 2331332 A CA2331332 A CA 2331332A CA 2331332 A1 CA2331332 A1 CA 2331332A1
- Authority
- CA
- Canada
- Prior art keywords
- protein
- cells
- angiogenic
- fragment
- tumstatin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102000004169 proteins and genes Human genes 0.000 title claims abstract 38
- 108090000623 proteins and genes Proteins 0.000 title claims abstract 38
- 238000000034 method Methods 0.000 title claims abstract 22
- 230000001772 anti-angiogenic effect Effects 0.000 title claims abstract 20
- 230000033115 angiogenesis Effects 0.000 claims abstract 4
- 239000012634 fragment Substances 0.000 claims 37
- 239000002157 polynucleotide Substances 0.000 claims 20
- 102000040430 polynucleotide Human genes 0.000 claims 20
- 108091033319 polynucleotide Proteins 0.000 claims 20
- 108010042086 Collagen Type IV Proteins 0.000 claims 9
- 102000004266 Collagen Type IV Human genes 0.000 claims 9
- 210000004027 cell Anatomy 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 8
- 102000037865 fusion proteins Human genes 0.000 claims 6
- 108020001507 fusion proteins Proteins 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 229920001184 polypeptide Polymers 0.000 claims 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 241000124008 Mammalia Species 0.000 claims 4
- 239000004480 active ingredient Substances 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 102000016387 Pancreatic elastase Human genes 0.000 claims 3
- 108010067372 Pancreatic elastase Proteins 0.000 claims 3
- 241000589516 Pseudomonas Species 0.000 claims 3
- 230000002491 angiogenic effect Effects 0.000 claims 3
- 238000010367 cloning Methods 0.000 claims 3
- 230000029087 digestion Effects 0.000 claims 3
- 230000014509 gene expression Effects 0.000 claims 3
- 239000000523 sample Substances 0.000 claims 3
- 102400000068 Angiostatin Human genes 0.000 claims 2
- 108010079709 Angiostatins Proteins 0.000 claims 2
- 102400001047 Endostatin Human genes 0.000 claims 2
- 108010079505 Endostatins Proteins 0.000 claims 2
- 241000238631 Hexapoda Species 0.000 claims 2
- 102400001051 Restin Human genes 0.000 claims 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 2
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 claims 2
- 230000001580 bacterial effect Effects 0.000 claims 2
- 108010038764 cytoplasmic linker protein 170 Proteins 0.000 claims 2
- 210000004962 mammalian cell Anatomy 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- 206010000050 Abdominal adhesions Diseases 0.000 claims 1
- 208000003120 Angiofibroma Diseases 0.000 claims 1
- 102400000729 Arresten Human genes 0.000 claims 1
- 101800001248 Arresten Proteins 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 102400000730 Canstatin Human genes 0.000 claims 1
- 101800000626 Canstatin Proteins 0.000 claims 1
- 208000003732 Cat-scratch disease Diseases 0.000 claims 1
- 208000032544 Cicatrix Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- FNQQBFNIYODEMB-UHFFFAOYSA-N Meticrane Chemical compound C1CCS(=O)(=O)C2=C1C=C(C)C(S(N)(=O)=O)=C2 FNQQBFNIYODEMB-UHFFFAOYSA-N 0.000 claims 1
- 206010029113 Neovascularisation Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000031481 Pathologic Constriction Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 206010043189 Telangiectasia Diseases 0.000 claims 1
- 102400000731 Tumstatin Human genes 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 206010052428 Wound Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 210000000601 blood cell Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 238000000502 dialysis Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 210000002950 fibroblast Anatomy 0.000 claims 1
- 238000005469 granulation Methods 0.000 claims 1
- 230000003179 granulation Effects 0.000 claims 1
- 230000001969 hypertrophic effect Effects 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 210000005229 liver cell Anatomy 0.000 claims 1
- 229960003738 meticrane Drugs 0.000 claims 1
- 239000000178 monomer Substances 0.000 claims 1
- 210000000663 muscle cell Anatomy 0.000 claims 1
- 230000002107 myocardial effect Effects 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 231100000241 scar Toxicity 0.000 claims 1
- 230000037387 scars Effects 0.000 claims 1
- 208000037804 stenosis Diseases 0.000 claims 1
- 230000036262 stenosis Effects 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 208000009056 telangiectasis Diseases 0.000 claims 1
- 230000010474 transient expression Effects 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 108010012374 type IV collagen alpha3 chain Proteins 0.000 claims 1
- 231100000397 ulcer Toxicity 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 210000005167 vascular cell Anatomy 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Reproductive Health (AREA)
- Biochemistry (AREA)
- Gynecology & Obstetrics (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8968998P | 1998-06-17 | 1998-06-17 | |
| US60/089,689 | 1998-06-17 | ||
| US12617599P | 1999-03-25 | 1999-03-25 | |
| US60/126,175 | 1999-03-25 | ||
| PCT/US1999/013737 WO1999065940A1 (en) | 1998-06-17 | 1999-06-17 | Anti-angiogenic proteins and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2331332A1 true CA2331332A1 (en) | 1999-12-23 |
Family
ID=26780845
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002331332A Abandoned CA2331332A1 (en) | 1998-06-17 | 1999-06-17 | Anti-angiogenic proteins and methods of use thereof |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1086129A1 (https=) |
| JP (3) | JP2002517999A (https=) |
| KR (1) | KR100682666B1 (https=) |
| CN (1) | CN1309663A (https=) |
| AU (1) | AU753249B2 (https=) |
| CA (1) | CA2331332A1 (https=) |
| IL (1) | IL140239A0 (https=) |
| WO (1) | WO1999065940A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6440729B1 (en) | 1995-06-30 | 2002-08-27 | University Of Kansas Medical Center | Treating angiogenesis-mediated diseases with the α2 monomer of type IV collagen |
| US6358735B1 (en) | 1995-06-30 | 2002-03-19 | University Of Kansas Medical Center | Method for inhibiting angiogenesis and tumors with the isolated NC1 α3 chain monomer of type IV collagen |
| US6962974B1 (en) | 1998-06-17 | 2005-11-08 | Beth Israel Deaconess Medical Center | Anti-angiogenic proteins and fragments and methods of use thereof |
| US6759047B1 (en) | 1998-06-17 | 2004-07-06 | Beth Israel Deaconess Hospital Corp. | Anti-angiogenic proteins and methods of use thereof |
| US7387779B2 (en) | 1998-06-17 | 2008-06-17 | Beth Israel Deaconess Medical Center | Anti-angiogenic proteins and fragments and methods of use thereof |
| US8128922B2 (en) | 1999-10-20 | 2012-03-06 | Johns Hopkins University | Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen |
| EP1337633A2 (en) * | 2000-01-07 | 2003-08-27 | Beth Israel Deaconess Medical Center | Anti-angiogenic proteins and fragments and methods of use thereof |
| CA2368681A1 (en) * | 2000-02-10 | 2001-08-16 | Zymogenetics, Inc. | Anti-angiogenic intestinal peptides, zdint5 |
| EP1363938B1 (en) | 2000-08-03 | 2013-12-11 | Johns Hopkins University | Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen |
| CN1455682A (zh) | 2001-01-05 | 2003-11-12 | 百疗医株式会社 | 包括编码抗－血管生成蛋白或者其部分的基因的用于类风湿性关节炎的基因治疗的组合物 |
| EP1389997B1 (en) * | 2001-04-13 | 2010-12-08 | Boyce Thompson Institute For Plant Research | Methods and compositions for stable transgenic plant pharmaceuticals and their use as contraceptives |
| CN100447155C (zh) * | 2001-05-23 | 2008-12-31 | 中国科学院上海上海生命科学研究院 | 具有抑制内皮细胞生长活性的重组人内皮生长抑制蛋白 |
| AU2002329643B2 (en) * | 2001-07-27 | 2006-11-16 | University Of Kansas Medical Center | Crystallized structure of type IV collagen NC1 domain hexamer |
| EP1644048B1 (en) | 2003-05-05 | 2015-04-29 | Johns Hopkins University | Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein |
| WO2006073970A2 (en) | 2005-01-06 | 2006-07-13 | The Johns Hopkins University | Rna interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by dna and transfected dendritic cell vaccines |
| JP4843767B2 (ja) * | 2005-08-31 | 2011-12-21 | 国立大学法人 岡山大学 | がん細胞特異的遺伝子発現法を用いた血管新生阻害薬 |
| US9085638B2 (en) | 2007-03-07 | 2015-07-21 | The Johns Hopkins University | DNA vaccine enhancement with MHC class II activators |
| CN101962404A (zh) * | 2010-06-17 | 2011-02-02 | 中国热带农业科学院热带生物技术研究所 | 一种用于治疗血管瘤的蛋白质 |
| DK2744831T3 (en) * | 2011-08-17 | 2018-03-05 | Univ Colorado Regents | TRANSFERRIN-TUMSTATIN-FUSION PROTEIN AND PROCEDURES FOR PREPARING AND USING THE SAME |
| WO2014180288A1 (zh) * | 2013-05-06 | 2014-11-13 | 中国药科大学 | 具有抑制肿瘤微环境血管再生和激活适应性免疫应答双功能的融合蛋白及其基因和应用 |
| CN111087477B (zh) * | 2020-01-03 | 2021-10-08 | 四川大学华西医院 | GBM-7S(α1)-NC1(α3)融合蛋白及其制备方法 |
| CN113735966B (zh) * | 2021-09-29 | 2022-11-01 | 陕西巨子生物技术有限公司 | 一种抗肿瘤重组胶原蛋白及其制备方法和应用 |
| CN119286901B (zh) * | 2024-11-21 | 2025-09-09 | 西安巨子生物基因技术股份有限公司 | 一种重组iv型胶原蛋白及其制备方法和应用 |
| CN120554490B (zh) * | 2025-05-28 | 2025-10-31 | 广西福莱明生物制药有限公司 | 一种重组iv型人源化胶原蛋白及其纯化工艺 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4876332A (en) * | 1987-10-08 | 1989-10-24 | Regents Of The Univeristy Of Minnesota | Polypeptides with type IV collagen activity |
| US5114840A (en) * | 1989-07-07 | 1992-05-19 | Karl Tryggvason | Method for determining the nucleotide sequence of a novel α5(IV) chain of human type IV collagen |
| US5354690A (en) * | 1989-07-07 | 1994-10-11 | Karl Tryggvason | Immunological methods for the detection of the human type IV collagen α5 chain |
| US5082926A (en) * | 1989-12-14 | 1992-01-21 | Regents Of The University Of Minnesota | Polypeptide with type iv collagen cell adhesion, spreading and motility activity |
| US5081031A (en) * | 1989-12-14 | 1992-01-14 | Regents Of The University Of Minnesota | Synthetic polypeptide with type iv collagen activity |
| US5424408A (en) * | 1990-11-30 | 1995-06-13 | Yale University | α-3 chain type IV collagen polynucleotides |
| US5731192A (en) * | 1993-08-27 | 1998-03-24 | Yale University | Collagen COL4A6: gene, protein and method of detecting collagen deficiency |
| US5567609A (en) * | 1994-06-30 | 1996-10-22 | University Of Kansas Medical Center | Use of isolated domains of type IV collagen to modify cell and tissue interactions |
-
1999
- 1999-06-17 WO PCT/US1999/013737 patent/WO1999065940A1/en not_active Ceased
- 1999-06-17 JP JP2000554765A patent/JP2002517999A/ja not_active Ceased
- 1999-06-17 AU AU45755/99A patent/AU753249B2/en not_active Ceased
- 1999-06-17 CN CN99808686A patent/CN1309663A/zh active Pending
- 1999-06-17 IL IL14023999A patent/IL140239A0/xx unknown
- 1999-06-17 CA CA002331332A patent/CA2331332A1/en not_active Abandoned
- 1999-06-17 EP EP99928762A patent/EP1086129A1/en not_active Ceased
- 1999-06-17 KR KR1020007014426A patent/KR100682666B1/ko not_active Expired - Fee Related
-
2007
- 2007-09-21 JP JP2007244618A patent/JP2008019271A/ja active Pending
-
2008
- 2008-06-24 JP JP2008164926A patent/JP2008301823A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2008301823A (ja) | 2008-12-18 |
| EP1086129A1 (en) | 2001-03-28 |
| AU753249B2 (en) | 2002-10-10 |
| IL140239A0 (en) | 2002-02-10 |
| KR100682666B1 (ko) | 2007-02-15 |
| AU4575599A (en) | 2000-01-05 |
| CN1309663A (zh) | 2001-08-22 |
| WO1999065940A1 (en) | 1999-12-23 |
| JP2002517999A (ja) | 2002-06-25 |
| KR20010053018A (ko) | 2001-06-25 |
| JP2008019271A (ja) | 2008-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7387779B2 (en) | Anti-angiogenic proteins and fragments and methods of use thereof | |
| AU753249B2 (en) | Anti-angiogenic proteins and methods of use thereof | |
| AU783662B2 (en) | Anti-angiogenic proteins and fragments and methods of use thereof | |
| US6759047B1 (en) | Anti-angiogenic proteins and methods of use thereof | |
| US6962974B1 (en) | Anti-angiogenic proteins and fragments and methods of use thereof | |
| US20080167227A1 (en) | Anti-angiogenic and anti-tumor properties of matin and other laminin domains | |
| EP1268798B1 (en) | Anti-angiogenic properties of vascostatin and fragments or variants thereof | |
| US20050255107A1 (en) | Anti-angiogenic proteins and fragments and methods of use thereof | |
| AU2001287274B2 (en) | Anti-angiogenic and anti-tumor properties of vascostatin and other nidogen domains | |
| AU2001245994B2 (en) | Anti-angiogenic and anti-tumor properties of matin and other laminin domains | |
| EP1719779A2 (en) | Antibodies against Matin | |
| US20080167232A1 (en) | Anti-angiogenic and anti-tumor properties of vascostatin and other indogen domains | |
| AU2001287274A1 (en) | Anti-angiogenic and anti-tumor properties of vascostatin and other nidogen domains | |
| AU2001245994A1 (en) | Anti-angiogenic and anti-tumor properties of matin and other laminin domains |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |